Search Results - "Caringal, Y"

Arylpropanolamines : Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations by WASHBURN, W. N, HARPER, T. W, DEJNEKA, T, AHMED, S, CARINGAL, Y, HANGELAND, J, ZHANG, M, CHENG, P. T. W, RUSSELL, A. D, SKWISH, S, SLUSARCHYK, D. A, ALLEN, G. T, WU, G, FROHLICH, B. H, ABBOA-OFFEI, B. E, CAP, M, WALDRON, T. L, GEORGE, R. J, TESFAMARIAM, B, DICKINSON, K. E, SEYMOUR, A. A, SHER, P. M, GODFREY, J. D, MCCANN, P, GIROTRA, R, SHAO, C, ZHANG, H, GAVAI, A, MIKKILINENI, A

Get full text

Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach by Smith, Roger A, Barbosa, James, Blum, Cheri L, Bobko, Mark A, Caringal, Yolanda V, Dally, Robert, Johnson, Jeffrey S, Katz, Michael E, Kennure, Nancy, Kingery-Wood, Jill, Lee, Wendy, Lowinger, Timothy B, Lyons, John, Marsh, Vivienne, Rogers, Daniel H, Swartz, Stephen, Walling, Tracy, Wild, Hanno

“…Heterocyclic ureas, such as N-3-thienyl N′-aryl ureas, have been identified as novel inhibitors of raf kinase, a key mediator in the ras signal transduction…”
Get full text

Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent by Khire, Uday R., Bankston, Donald, Barbosa, James, Brittelli, David R., Caringal, Yolanda, Carlson, Robert, Dumas, Jacques, Gane, Todd, Heald, Sarah L., Hibner, Barbara, Johnson, Jeffrey S., Katz, Michael E., Kennure, Nancy, Kingery-Wood, Jill, Lee, Wendy, Liu, Xiao-Gao, Lowinger, Timothy B., McAlexander, Ian, Monahan, Mary-Katherine, Natero, Reina, Renick, Joel, Riedl, Bernd, Rong, Hong, Sibley, Robert N., Smith, Roger A., Wolanin, Donald

“…Bis-aryl ureas have been disclosed previously as a potent class of Raf kinase inhibitors. Modifications in the amide portion led to an improvement in aqueous…”
Get full text

Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations by Washburn, W N, Harper, T W, Wu, G, Godfrey, J D, McCann, P, Girotra, R, Shao, C, Zhang, H, Gavai, A, Mikkilineni, A, Dejneka, T, Ahmed, S, Caringal, Y, Hangeland, J, Zhang, M, Cheng, P T W, Russell, A D, Skwish, S, Slusarchyk, D A, Allen, G T, Frohlich, B H, Abboa-Offei, B E, Cap, M, Waldron, T L, George, R J, Tesfamariam, B, Dickinson, K E, Seymour, A A, Sher, P M

“…Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines 1 as selective beta(3) agonists is complicated by their propensity to undergo…”
Get full text

Arylpropanolamines: Selective beta sub(3) agonists arising from strategies to mitigate phase I metabolic transformations by Washburn, W N, Harper, T W, Wu, G, Godfrey, J D, McCann, P, Girotra, R, Shao, C, Zhang, H, Gavai, A, Mikkilineni, A, Dejneka, T, Ahmed, S, Caringal, Y, Hangeland, J, Zhang, M, Cheng, PTW, Russell, AD, Skwish, S, Slusarchyk, DA, Allen, G T, Frohlich, B H, Abboa-Offei, B E, Cap, M, Waldron, T L, George, R J, Tesfamariam, B, Dickinson, KE, Seymour, A A, Sher, P M

“…Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines 1 as selective beta sub(3) agonists is complicated by their propensity to undergo…”
Get full text

Arylpropanolamines: Selective β 3 agonists arising from strategies to mitigate phase I metabolic transformations by Washburn, W.N., Harper, T.W., Wu, G., Godfrey, J.D., McCann, P., Girotra, R., Shao, C., Zhang, H., Gavai, A., Mikkilineni, A., Dejneka, T., Ahmed, S., Caringal, Y., Hangeland, J., Zhang, M., Cheng, P.T.W., Russell, A.D., Skwish, S., Slusarchyk, D.A., Allen, G.T., Frohlich, B.H., Abboa-Offei, B.E., Cap, M., Waldron, T.L., George, R.J., Tesfamariam, B., Dickinson, K.E., Seymour, A.A., Sher, P.M.

“…Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines 1 as selective β 3 agonists is complicated by their propensity to undergo metabolic…”
Get full text

p38 Kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas by Redman, Anikó M, Johnson, Jeffrey S, Dally, Robert, Swartz, Steve, Wild, Hanno, Paulsen, Holger, Caringal, Yolanda, Gunn, David, Renick, Joel, Osterhout, Martin, Kingery-Wood, Jill, Smith, Roger A, Lee, Wendy, Dumas, Jacques, Wilhelm, Scott M, Housley, Timothy J, Bhargava, Ajay, Ranges, Gerald E, Shrikhande, Alka, Young, Deborah, Bombara, Michael, Scott, William J

“…Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl,…”
Get full text

Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor by Dumas, Jacques, Hatoum-Mokdad, Holia, Sibley, Robert N, Smith, Roger A, Scott, William J, Khire, Uday, Lee, Wendy, Wood, Jill, Wolanin, Donald, Cooley, Jeffrey, Bankston, Donald, Redman, Aniko M, Schoenleber, Robert, Caringal, Yolanda, Gunn, David, Romero, Romulo, Osterhout, Martin, Paulsen, Holger, Housley, Timothy J, Wilhelm, Scott M, Pirro, John, Chien, Du-Shieng, Ranges, Gerald E, Shrikhande, Alka, Muzsi, Andrew, Bortolon, Elizabeth, Wakefield, Jean, Gianpaolo Ostravage, Cynthia, Bhargava, Ajay, Chau, Thuy

“…Inhibitors of the MAP kinase p38 provide a novel approach for the treatment of osteoporosis, inflammatory disorders, and cancer. We have identified N-(3-…”
Get full text

A new route to benzo[a]naphtahacene-8,13-diones : synthesis and revision of the structure proposed for G2N by HAUSER, F. M, CARINGAL, Y

Get full text

A new route to benzo[a]naphthacene-8,13-diones: synthesis and revision of the structure proposed for G2N by Hauser, Frank M, Caringal, Yolanda

Get full text